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Aim: One of the most prominent side effects of intensive cancer chemotherapy is bone marrow suppression which is an independent 
negative prognostic factor for the time to tumor progression. The aim of the study was to evaluate the myeloprotective possibilities 
of carbon enterosorbents in the case of usage of alkilating drug melphalan (L-PAM). Materials and Methods: L-PAM was in-
jected intravenously to healthy inbred rats to cause the myelosuppression. 3 days before and 7 days after this, suspension of two 
types of carbon granulated enterosorbents were administered per os one time per day. On 8th day after L-PAM injection, the rats 
were weighted and blood and liver tissue were taken under Ketamine general anesthesia for biochemical examination. Peripheral 
blood smears were made also. Results: Melphalan at a dose of 3 mg/kg causes expressed myelotoxic reaction: leucopenia, decre-
asing of erythrocytes, hemoglobin and platelets counts. Even on 8th day after single injection of this cytostatic we can detect expressed 
signs of oxidative stress like increasing of hydroperoxides, TBA-reactive substances, and decreasing of activity and level of main 
endogenic antioxidants — superoxide dismutase (SOD), catalase and reduced glutathione. L-PAM causes also the violation 
of kidney function such as increase of urea and creatinine level; and rising of endogenic intoxication with elevation of middle mass 
molecules level. In a dose of 3 mg/kg melphalan has no negative influence on liver function on 8th day of experiment. Enterosorption 
with carbon enterosorbents C1 (bulk density γ = 0.28 g/cm3, granules diameter 0.15–0.25 mm, BET pore surface 1719 m2/g, 
therapeutic dosage 1400 mg/kg) and C2 (bulk density γ = 0.18 g/cm3, granules diameter 0.15–0.25 mm, BET pore surface 
2162 m2/g, therapeutic dosage 900 mg/kg) diminishes and mitigates negative side effects caused by single intravenous injection 
of melphalan. Carbon enterosorbent C2 have rather more expressed positive effect than C1 for practically all indices. The most 
important curative effect due to C2 administration is prominent myeloprotection of bone marrow of experimental animals. Conclu-
sion: Carbon enterosorbent C2 is promising and perspective sorbent for prophylaxis and treatment of side effects of cytostatic 
chemotherapy including myelotoxicity, mucositis, kidney injuries, gonadotoxicity, etc.
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Enterosorption with carbon sorbents is a well-
known method of sorption therapy, which is widely 
used for combined treatment of exogenic and endo-
genic intoxications of different origin [1–4] including 
toxic reaction attributable to intensive cancer therapy.
Melphalan (L-phenylalanine mustard, phenylala-
nine mustard, L-PAM, or L-sarcolysin) is a phenylala-
nine derivative of nitrogen mustard. It is a bifunctional 
alkylating agent and one of the most aggressive an-
tineoplastic drugs [5]. Before their use in chemo-
therapy, alkylating agents better known for their use 
as sulfur mustard, “mustard gas” and related chemical 
weapons in World War I. Its hematological suppres-
sion effects are known since sixties [6]. Bone marrow 
suppression is the most significant toxicity associated 
with L-PAM, especially in case of intravenous injection. 
Thrombocytopenia and/or leukopenia are indications 
to withhold further therapy until the blood counts have 
sufficiently recovered.
It is known that detoxification procedures with 
the use of carbon adsorbents have myeloprotective 
action. The first fact [7] is related to an influence 
of hemocarboperfusion, i.e. passing blood through 
column with activated carbon, on survival rate of dogs 
irradiated with minimal absolutely lethal dose with en-
hancing its survival rate from 3.2% to 60–70%.
It’s is important, too, that enterosorption demon-
strates also certain positive effect in severe radiation 
injuries combined with thermal trauma [8, 9].
The reputed fact — alkylating anticancer prepa-
rations have radiomimetic mechanism of their 
cytostatic action mimicking cytostatic effects of ir-
radiation [10, 11]. Principal action of alkylating drugs, 
 including melphalan that is a “nitrogen mustard” de-
rivative, related to their covalent interaction with bases 
of DNA chain with generation of adducts that hinder 
DNA replication and, consequently, stops cell divi-
sion as it happens during irradiation. At present time, 
it is possible to study melphalan-DNA-adducts forma-
tion on the level of separate haemopoietic cells [12].
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The second fact is directly related to myelode-
pression caused by alkylating preparations. In this 
study [13] cyclophosphan preparation was admini-
stered to rats with transplanted Guerin carcinoma 
at the dose of 100 mg/kg of body weight on 10th and 13th 
days after tumor transplantation, while enterosorption 
with the use of synthetic SCN carbons (bulk density 
0.3–0.4 g/cm3) was initiated from the next day after 
cyclophosphan injection. In this case enterosorption 
shows an evident myeloprotective effect toward all 
main elements of bone marrow.
The presence of myeloprotective effect of carbon 
enterosorbents was also observed during treatment 
of patients with lymphogranulomatosis irradiated 
by radical scheme [14]. Silicon-organic enterosorbents 
were also used in patients with different tumors of peri-
toneal cavity who underwent polychemotherapy [15].
Apart of myelotoxicity, melphalan possesses definite 
hepatotoxicity that is notably manifested in the case 
of injection into hepatic artery [16]. Upon isolated he-
patic perfusion expression of melphalan-dependent 
tumor necrosis factor (TNF) pathogenic pathways via 
activation of both of TNF-receptors in Kupffer cells was 
demonstrated as an important component of melphalan 
toxicity [17]. These receptors are also a target for bacte-
rial lipopolysaccharide, which intensively enters portal 
blood flow upon different intestinal injuries. It is known 
for a long time about gastro-intestinal to xicity (GIT) 
of melphalan that may result in the development of mu-
cosa injuries (mucositis) and other manifestations 
of enteropathy, including hemorrhagic diarrhea and 
penetration of large bowel [18, 19].
At the same time, enterosorption causes an ex-
pressed curative effect in the case of different liver 
pathologies, like viral and toxic hepatitis as well 
as mechanical jaundice [20–25]. On other side there 
are multiple demonstrations of favorable action of en-
terosorption in the treatment of various GIT mucosa 
injuries, including the ones caused by radiation and 
severe burn toxicities [8] or enteric disbiosis [26], 
as well as for prevention of intestinal flora translo-
cation [27]. As was found above, enterosorption 
mitigates the signs of oxidative stress [28, 29] due 
the activation of excessive lipid peroxidation which 
is a stereotype reaction of organism toward administra-
tion of alkylating preparations [30]. Enterosorption also 
corrects “metabolic chaos” that develops in a body 
upon action of radiation or radiomimetics caused 
by disturbed coordination in the functioning of various 
enzymatic systems [31, 32]. It is also important to note 
that enterosorption diminishes the direct and delayed 
toxic reactions of patients (nausea, vomiting etc.) after 
intensive chemotherapy [33, 34].
Thus, it is reasonable to use carbon sorbents for 
mitigation of symptoms of melphalan polipathic iatro-
genic intoxication.
MATERIALS AND METHODS
Animals and experiment design. The studies 
were carried out on 55 white inbred rats weighting 200 ± 
20 g from the R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology (IEPOR) vivari-
um. All animals’ procedures had been done according 
to the rules and requirements of European Conven-
tion for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes and local 
Ethic Committee of IEPOR.
Evaluation of sorption properties of carbon 
sorbents was performed by standard methods, 
an impact of microporous structures was calculated 
by Dubinin — Radushkevich model, pore distribution 
by sizes — by Brunauer— Emmett — Teller model, 
mesopore area — by the method proposed by Barrett, 
Joyner and Halenda [35].
Animals were randomly distributed into 4 groups: 
1 — intact group (n = 25); 2 — rats who had got L-PAM 
(n = 10) — control group; 3 — L-PAM and carbonic en-
terosorbent C1(L-PAM + C1) (n = 10); and 4 —  L-PAM 
and carbonic enterosorbent C2 (L-PAM + C2) (n = 10). 
The absorption of oral melphalan is highly variable due 
to incomplete intestinal absorption, differences in “first 
pass” hepatic metabolism, and rapid hydrolysis. Oral 
administration of melphalan with a high fat meal may 
reduce melphalan exposure (AUC) by 36 to 54% [35]. 
That’s why we chose intravenous administration 
of L-PAM (AlkeranTM Injection, GlaxoSmithKline, UK). 
It has been injected at once in tail vein at the dose 
of 3.0 mg/1 kg body weight.
We used carbonic granulated enterosor-
bents C1 of IEPOR production with bulk density 
γ = 0.28 g/cm3, with coincides with enterosorbents, 
used by L.V. Bonatskaya (1985) and highly activated 
enterosorbents C2 with γ = 0.18 g/cm3. Both enterosor-
bents have granules with diameter of 0.15–0.25 mm, 
and used in the dose of 5 ml per 1 kg of animals 
body weight or 1400 mg/kg for C1 enterosorbent 
and 900 mg/kg for C2. A suspension of enterosor-
bents in appropriate quantity of distilled water was 
introduced via the tube into rat stomach once a day 
during 3 days before the day of L-PAM injection and 
7 days after injection during 7 days one time per a day. 
Rats of control (L-PAM) and intact groups were given 
equivalent quantity of distilled water. Animals of intact 
group received IV equal quantities of physiologic solu-
tion instead of L-PAM.
On 8th day since L-PAM injection, the rats were 
weighted and blood was taken from the heart under 
ketamine hydrochloride general anesthesia. Peri-
pheral blood smears were made also. For the sta-
ining of cytological smears we used panoptic method 
of Pappenheim, using May-Grünwald and Giemsa so-
lutions [36]. The main hematologic indices were ana-
lyzed on hematology analyzer BC-3000Plus Mindray. 
Plasma activity of aspartate aminotransfe rase (AST) 
and alanine aminotransferase (ALT), alkaline phos-
phatase, concentration of total bilirubin, serum total 
protein, creatinine and urea were analyzed using 
a standard kits “Lachema” on Humalyzer 2000. Serum 
level of middle mass molecules (MMM) [37], thiobarbi-
turic acid-reactive substances (TBARS) [38], catalase 
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activity [39] were studied. Plasma ceruloplasmin (CP) 
level was studied also [40]. The liver tissue was ho-
mogenized by using the homogenizer SilentCrusher S 
(Heidolph, Germany). In liver homogenates we studied 
the concentration of lipid hydroperoxides [41], TBARS, 
superoxide dismutase (SOD) [42], catalase activity 
and reduced glutathione level (G-SH) [43].
Statistical analysis. The data are expressed 
as the mean ± standard error of the mean (M ± m). 
Probability values p < 0.05 were considered sta-
tistically significant. The statistical significance 
of the diffe rences between mean values was assessed 
by the Mann — Whitney-test and ANOVA-test using 
Microsoft Excel ХР (USA) and Origin 7.5 (OriginLab 
Corporation, USA). The distribution of indices was 
estimated by using Shapiro — Wilk Normality Test.
RESULTS
On 8th day after single intravenous injection 
of L-PAM at a dose of 3 mg•kg-1 we detected signifi-
cant decrease of leukocytes count by 72.5%, eryth-
rocytes count — by 12.4%, hemoglobin level (HB) — 
by 7.7% and platelets — by 18.6% (Table 1). Entero-
sorbent C1 promoted 2-fold increase of leukocyte 
count, C2 — 4.5-fold increase. C2 was more effective 
than C1: increase of leukocyte count was by 117.4% 
higher than in L-PAM+C1 group. On the base of non-
essential changes of erythrocytes count, HB and plate-
lets count after L-PAM injection both enterosorbents 
C1 and C2 did not alter these indices.
Table 1. Hematological rats’ indices, M ± m
Parameter
Animal’s groups
Intact rats
(n = 25)
L-PAM
(n = 10)
L-PAM + C1
(n = 10)
L-PAM + C2
(n = 10)
WBC, ×109/l 5.24±0.29 1.44±0.14* 2.98±0.24# 6.48±0.37#γ
RBC, ×1012/l 7.34±0.12 6.43±0.11* 6.53±0.13 6.71±0.06
HB, g/l 134.32±1.69 124.0±2.37* 122.0±1.53 127.40±3.44
PLt, ×109/l 634.84±22.97 517.0±26.54* 471.90±31.17 499.60±16.89
Notes: statistical significance р < 0.05 comparatively with: *intact rats; 
#L-PAM; γL-PAM + C1.
Concerning the leukocytes formula on 8th day after 
 L-PAM injection we can see the significant increase 
of neutrophils percentage — by 51.1% (Table 2). Also 
we can observe the appearance of young forms of granu-
locytes in peripheral blood smears and basophils, espe-
cially in group L-PAM + C2. All others sprouts of blood 
have no statistical significance in percentage data.
Table 2. Leukocytes formula, M ± m, %
Parameter
Animal’s groups
Intact rats
(n = 25)
L-PAM
(n = 10)
L-PAM + C1
(n = 10)
L-PAM + C2
(n = 10)
Promyelocytes − − − 0.78±0.57
Myelocytes − − − 1.11±1.11
Metamyelocytes − − 2.28±2.14 1.33±1.10
Neutrophils 25.90±1.83 39.14±3.49* 41.43±4.61 32.67±3.18
Eosinophils 1.0±0.45 0.57±0.37 0.57±0.37 0.44±0.29
Basophils − − − 0.22±0.22
Lymphocytes 68.40±3.10 54.71±4.52 50.86±5.50 58.89±3.64
Monocytes 4.70±0.97 5.58±1.51 4.86±1.68 4.56±1.36
Notes: statistical significance р < 0.05 comparatively with: *intact rats; 
#L-PAM; γL-PAM + C1.
Rather more interesting picture give us the chang-
es of absolute count of different types of leuco-
cytes (Table 3). After L-PAM injection the absolute 
quantity of neutrophils is lower by 58.5%, lymphocytes 
count — by 78.0% comparing with intact rats. C1 ad-
ministration caused the rising of neutrophils quantity 
by 119.0%, lymphocytes — by 92.4% in comparison 
with untreated control. Enterosorbent C2 had more 
prominent effects: absolute number of neutrophils 
was by 275.5% (3.8-fold) higher comparatively with 
L-PAM group; and by 71.5% higher comparatively 
with L-PAM + C1 group. At the same time lymphocytes 
quantity in  L-PAM-C2 group is by 384.3% (4.8-fold) 
higher in L-PAM group and by 151.8% (2.5-fold higher) 
in comparison with intact control.
Table 3. Leukocytes formula count, M ± m, ×109/l
Parameter
Animal’s groups
Intact rats
(n = 25)
L-PAM
(n = 10)
L-PAM + C1
(n = 10)
L-PAM + C2
(n = 10)
Promyelocytes, ×109/l − − − 0.05±0.04
Myelocytes, ×109/l − − − 0.07±0.07
Metamyelocytes, ×109/l − − 0.07±2.14 0.09±0.07
Neutrophils, ×109/l 1.37±0.09 0.56±0.05 * 1.23±0.14# 2.12±0.21#γ
Eosinophils, ×109/l 0.05±0.02 0.01±0.01 0.02±0.01 0.03±0.02
Basophils, ×109/l − − − 0.01±0.01
Lymphocytes, ×109/l 3.58±0.16 0.79±0.06* 1.52±0.16# 3.82±0.24#γ
Monocytes, ×109/l 0.24±0.05 0.08±0.02 0.14±0.05 0.29±0.09
Notes: statistical significance р < 0.05 comparatively with: *intact rats; 
#L-PAM; γL-PAM + C1.
L-PAM in case of single intravenous injection 
at a dosage of 3 mg•kg-1 body weight to healthy inbred 
white rats didn’t have negative influence on liver func-
tion (Fig. 1): there were no definite changes in activity 
of ALT and total bilirubin level. The activities of AST and 
alkaline phosphatase decreased by 19.2 and 39.3% 
respectively, maybe due to L-PAM-dependent inhibi-
tion of the synthesis of these enzymes.
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Fig. 1. The liver function indexes in experimental animals treated 
with enterosorbents and L-PAM.
Notes: statistical significance p ≤ 0.05 comparatively with: *intact 
rats; #L-PAM group; γL-PAM + C1 group
All changes in hepatic indices due to enterosorption 
are also located in the borders of its normal value. 
Still enterosorbents C1 and C2 caused significant 
decre asing of ALT (by 12.5 and 15.0%) and total bili-
rubin level (by 19.8 and 20.4%, respectively). Activity 
of alkaline phosphatase increased by 59.5% under 
influence of C1, and by 38.0% under the influence 
of C2 in comparison with the rats of L-PAM-group, but 
the last index was significantly lower than in intact rats.
L-PAM caused the kidney malfunction: urea and 
creatinine serum levels were increased by 124.8 and 
11.6%, respectively (Table 4). The urea content un-
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der the influence of C1 and C2 was lower by 37.2% 
and 44.8%, respectively, in comparison with L-PAM 
group. Sorbent C2 caused the decrease of creatinine 
level by 7.5%, but C1 had no influence on this index. 
At the same time the signs of activation of synthetic 
liver function were seen. The total serum protein 
level in case of enterosorption was higher by 15.2 and 
28.2% respectively for C1 and C2, than in untreated 
and L-PAM groups.
Table 4. The indices of blood serum, M ± m, n = 10
Index Intact rats L-PAM L-PAM + C1 L-PAM + C2
Total serum 
protein, g/l
51.04±2.53 51.65±1.66 59.50±2.62# 66.20±2.83#
Urea, mmol/l 4.92±0.19 11.06±0.49* 6.94±0.28# 6.10±0.37#
Creatinine, 
mcmol/l
71.72±1.94 80.06±1.92* 78.42±1.45 74.02±1.16#γ
МMМ1, u/l 0.327±0.022 0.606±0.013* 0.456±0.032# 0.429±0.038#
МMМ2, u/l 0.448±0.029 0.610±0.022* 0.483±0.020# 0.455±0.029#
Notes: statistical significance р < 0,05 comparatively with: *intact rats; 
#L-PAM; γL-PAM + C1.
Levels of MMM1 and MMM2 as indices of endo-
genic intoxication were higher by 85.4 and 36.0% 
respectively in L-PAM-treated rats comparatively with 
intact rats. Enterosorption effectively decreased these 
indexes: in L-PAM + C1 group levels of MMM1 and 
MMM2 were lower by 24.8 and 20.7% and in L-PAM 
+ C2 group — by 29.2 and 25.4%, respectively, 
 comparing with L-PAM group (see Table 4).
The biochemical sings of intensive oxidative stress 
were detected after L-PAM administration (Table 5). 
On 8th day after IV injection of L-PAM the levels 
of HPL and TBARS in liver tissue were increased 
by 100.2 and 71.3%, respectively; TBARS in blood 
serum — by 126.6% in comparison with intact group. 
The decrease of activity of SOD (on 68.7%) and 
catalase in liver homogenates and blood serum was 
by 26.5 and 53.0%, respectively. At the same time 
the levels of G-SH and CP were lower by 10.7 and 
19.8%, respectively, compared to control group.
Table 5. Changes of prooxidant-antioxidant system indices, M ± m, n = 10
Index Intact rats L-PAM L-PAM + C1 L-PAM + C2
HPL, U/kg 2.19±0.05 4.38±0.21* 3.03±0.21# 2.26±0.15#γ
TBARS (liver), 
mcmol/kg
7.04±0.16 12.07±0.28* 9.08±0.50# 7.26±0.49#γ
TBARS (serum), 
mcmol/l
0.36±0.04 0.82±0.05* 0.71±0.05 0.58±0.05#
SOD (liver), U/kg 75.96±1.94 23.81±2.50* 24.31±2.55 50.38±2.82#γ
Catalase (liver), 
cat/kg
65.43±1.27 48.06±3.15* 57.51±1.80# 59.36±3.04#
Catalase (se-
rum), cat/l
6.13±0.33 2.88±0.58* 3.97±0.71 8.50±0.40#γ 
G-SH, mmol/kg 2.03±0.05 1.81±0.03* 1.94±0.05 2.07±0.06#
CP, mg/l 322.88±11.62 259.0±12.61* 269.5±16.99 301.0±11.44#
Notes: statistical significance р < 0.05 comparatively with: *intact rats; 
#L-PAM; γL-PAM + C1.
As one can see, enterosorption have significant 
posi tive influence on the processes of excessive lipid 
peroxidation. C1 decreased of HPL and TBARS level 
in the liver by 30.8 and 24.7%, but there were no signifi-
cant effects on serum TBARS, catalase, CP and SOD 
in the liver. At the same time the rise of activity of liver 
catalase by 19.7% under the influence of C1 enterosor-
bent was seen. C2 enterosorbent had more prominent 
effects. The HPL level was by 48.4% less than in L-PAM 
group and by 25.4% less than in L-PAM + C1 group, 
TBARS quantity in liver homogenates was by 39.9% 
lower than in untreated group and 20.1% lower than 
in rats which got C1. The decrease of TBARS in the se-
rum by 29.1% was also registered.
Enterosorbent C2 promoted more significant restora-
tion of antioxidant system: activity of SOD, and catalase 
in liver and serum was higher by 111.6; 23.5 and 19.1% 
respectively than in L-PAM group; G-SH level and CP also 
increased by 14.5 and 16.2%. Furthermore, liver SOD 
and serum catalase activities were by 107.3 and 114.1% 
higher than in L-PAM + C1 group (see Table 5).
So, the difference in efficacy of enterosorbents 
C1 and C2 is very considerable, that’s why we should 
estimate their structural and sorption parameters more 
meticulously.
As one can see on porograms (Fig. 2) the pore sys-
tems for nitrogen sorption of both samples are similar 
in the range of 10–500 Å. The main difference between 
C1 and C2 is that the porous structure of C2 is more de-
veloped and shifted toward mesopores, which is con-
firmed by the ratio of the total surface area of the pore 
size and surface calculated by BJH model (Table 6).
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Fig. 2. The pore size distribution of enterosorbents 
С1 (0.28 g/cm3) and С2 (0.18 g/cm3)
Table 6. The specific surface area
Samples Total surface area, m
2/g
ВЕТ DR BJH
C1 1719 1639 239
C2 2162 2049 565
Notes: pore distribution calculation by: ВЕТ — Brunauer — Emmett —  Teller 
model; BJH — Barrett — Joyner — Halenda model; DR — Dubinin – Radu-
shkevich model.
In case of calculating of total surface sorp-
tion (ВЕТ) taking into account the difference between 
bulk density (γ, g/cm3) of samples, the specific surface 
area of C2 is less than for C1 (1390 versus 1719 m2/g), 
the assessment of micropore surface (DR) shows 
the same results C1>C2 (1639 versus 1317 m2/g). 
At the same time the surface of C2 mesopores is larger 
than C1 (363 toward 239 m2/g).
In Table 7 one can see the data of adsorption 
of freely soluble markers by enterosorbents C1 and C2: 
the standard dose of C2 is more effective than C1 for 
sorption of middle molecular weight substances (vi-
tamin B12) and low molecular weight substances 
(methylene blue) by 2- and 2.6-fold respectively, and 
is not significantly lower for adsorption of creatinine 
compared with C1.
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From Table 8 one may see that enterosorbent 
C2 exceeds C1 by the sorption of strongly bound 
ligands (unconjugated bilirubin) by 29.3%, but it is al-
most equal by the protein adsorption.
Those data demonstrate that despite of definite 
range of similarity between porograms of C1 and 
C2 carbon these enterosorbents have considerable 
quantitative and qualitative differences in spectra 
of metabolite adsorption.
Table 7. The adsorption of hydrophilic marker metabolites by enterosor-
bents C1 and C2
Sam-
ples Υ, g/cm
3 Vs, 
cm3/g
С residu-
al, mg/ml
Adsorp-
tion, 
mg/g
at С eq. 
0.951 mg/
ml, mg/g
Recalculation 
on capacity vo-
lume, mg/cm3
Methylene blue
С1 0.28 0.87 0.951 218.15 218.15 61.08
С2 0.18 2.02 0.443 420.0 901.62 162.3
Initial concentration 1.5 mg/ml
Creatinine
С1 0.28 0.87 0.0968 79.43 79.43 22.24
С2 0.18 2.02 0.0807 86.85 104.18 18.75
Initial concentration 0.3 mg/ml
В12
С1 0.28 0.87 0.69 123.6 123.6 34.61
С2 0.18 2.02 0.425 229.24 372.18 67.0
Initial concentration 1.0 mg/ml
Table 8. The adsorption of unconjugated bilirubin and protein (albumin) 
by enterosorbents C1 and C2
Sam-
ples Υ, g/сm
3 Vs, 
сm3/g
С resi-
dual,  
mg%
Adsorp-
tion, 
mg/g
at С eq. 
15.75 mg%, 
mg/g
Recalculation 
on capacity vo-
lume, mg/сm3
Bilirubin
С1 0.28 0.87 15.75 8.42 8.42 2.36
С2 0.18 2.02 12.43 14.65 18.56 3.34
Initial concentration 20.0 mg%
Protein
С1 0.28 0.87 25.49 0.695 0.695 0.195
С2 0.18 2.02 24.65 0.960 0.960 0.173
Initial concentration 30.0 g/l
DISCUSSION
Usually adjuvant or neoadjuvant polychemotherapy 
is too toxic toward healthy cells of the body to be ef-
fective. In multivariate analysis, hematological toxicity 
retained its imperative as an independent negative 
prognostic factor for time to disease progression [44]. 
That’s why the effective and safe methods which 
replenish the hematological indices and protect 
the patient from febrile neutropenia and other bacte-
rial complication during polychemotherapy courses 
are very important.
As it is follows from experimental data, enterosorp-
tion can be one of such methods. In case of C1 and 
C2 enterosorbents administration prominent myelo-
protective effect was observed. Leucocytes count was 
significantly higher in L-PAM + C2 group: in compari-
son with L-PAM and L-PAM + C1 groups and even with 
intact rats — at least by 23.6%. There was the tendency 
to rising of other hematological indices, too.
Enterosorption also demonstrated prominent 
potential suppression for oxidative stress caused 
by L-PAM. For almost all indices of prooxidant-an-
tioxidant system C2 enterosorbent has the definite 
advantages comparatively with C1 enterosorbent 
especially for indices of endogenous antioxidant de-
fense. As it is known such enzymes as SOD, catalase 
and peroxidase act as potent radioprotectors, being 
the scavengers of free radicals and oxygen metabo-
lites. These enzymes serve as the first line of defense 
of DNA, membranes, proteins and cell metabolic pro-
cesses against peroxidation injury [45]. Also irradiation 
causes the changes of high molecular components 
of cells resulting which in inactivation of catalase and 
other antioxidant enzymes, while excessive quantity 
of peroxides and other highly reactive components leads 
to their inhibition [46]. Melphalan being one of the most 
proximate radiomimetic also can exhibit the same 
mechanism of antioxidant enzymes inactivation.
Endogenic intoxication in oncologic patients could 
be caused by tumor disposition as well as by curable 
measures (chemotherapy, surgical treatment and 
radiotherapy) and results in significantly impaired 
quality of life of such patients, limited special treatment 
modalities, renal, hepatic and enteric malfunction, 
and increased mortality. In turn, prominent syndrome 
of endogenic intoxication aggravates toxic side ef-
fects of aggressive therapy. So, it seems reasonable 
to use accompanying detoxification therapy [47, 48], 
in particular, enterosorption.
Enterosorption as a part of efferent therapy be-
sides its local effects in intestine, has distant effects, 
which are expressed in improvement of the function 
of the body detoxification systems, enhancement 
of different metabolic processes [48, 49].
The exact mechanisms of myeloprotection due to en-
terosorption remain largely unknown. However, it has been 
shown that they may include the decrease and mitigation 
of the signs of endogenic intoxication, by suppression 
of excessive lipid peroxidation. In our study we explain 
the increase of white blood cell count by the improvement 
of antioxidant defense of bone marrow.
On the other hand, the processes of bone mar-
row cell proliferation, migration, and homing are 
downregulated by many factors including adhesion 
molecules, cytokines, proteolytic enzymes, stromal 
cells, and hematopoietic cells [50]. Still, we know that 
enterosorption influences the level of different types 
of cytokines [51, 52]. It is quite possible that carbon 
enterosorbents may bind some toxic substances 
inhibiting the proliferation of bone marrow cells or op-
positely — promote the increased content of factors 
which stimulate sanguification.
Repeated sessions of chemotherapy inevitably 
result in cumulative myelosuppression, probably due 
to chronic stem cell depletion. Protection of the stem 
cell compartment during each cytotoxic treatment 
with the use of enterosorption may prevent such 
events [53]. Our data have demonstrated that entero-
sorption with carbon sorbents has prominent myelo-
protective activity especially expressed in the case 
of usage of superactivated carbon enterosorbent C2.
In conclusion, melphalan at a dose of 3 mg/kg causes 
expressed myelotoxic reaction such as leucopenia, de-
crease of erythrocyte and platelet counts, and hemo-
globin concentration. Even on 8th day after single injec-
tion of this cytostatic one can detect expressed signs 
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of oxidative stress like increase of hydroperoxides, 
TBA-reactive substances, and decrease of activity 
and level of the main endogenic antioxidants — SOD, 
catalase and reduced glutathione. L-PAM causes also 
the violation of kidney function such as increase of urea 
and creatinine levels and endogenic intoxication with 
elevation of MMM level. At a dose of 3 mg/kg melpha-
lan has no negative influence on liver function. Entero-
sorption with carbon enterosorbents C1 (bulk density 
γ = 0.28 g/cm3, granules diameter 0.15–0.25 mm, 
BET pore surface 1719 m2/g, therapeutic dosage 
1400 mg/kg) and C2 (bulk density γ = 0.18 g/cm3, 
granules diameter 0.15–0.25 mm, BET pore surface 
2162 m2/g, therapeutic dosage 900 mg/kg) diminishes 
and mitigates negative side effects caused by single 
intravenous injection of melphalan. Carbon enterosor-
bent C2 have rather more expressed positive effect 
than C1 for practically all indices. The most important 
curative effect due to C2 administration is prominent 
myeloprotection of bone marrow of experimental 
animals.
Carbonic enterosorbent C2 is promising and per-
spective sorbent for prophylaxis and treatment of side 
effects of cytostatic chemotherapy which include my-
elotoxicity, mucositis, kidney injuries, gonadotoxicity, etc.
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